Medtronic Outpaces Abbott on Dividend Yield and Growth

Medtronic and Abbott Laboratories stand as two of the most enduring dividend payers in the medical device sector, each with nearly half a century of consecutive annual increases. Medtronic currently offers a forward annualized yield of 3.11% with a quarterly payout of $0.72, supported by 49 consecutive years of growth. Abbott Laboratories provides a 2.4% yield on a $2.52 annualized payout, backed by 54 consecutive years of increases and a recent quarterly hike from $0.59 to $0.63. For investors prioritizing immediate income, Medtronic’s higher payout ratio relative to its operating cash flow of $7.33 billion in fiscal year 2026 makes it the more attractive cash generator.

The underlying business trajectories of the two firms diverge significantly in terms of revenue composition and recent momentum. Abbott Laboratories reported second-quarter 2026 revenue of $12.59 billion, a 13.02% year-over-year increase, driven by its diversified portfolio that includes diagnostics, pharmaceuticals, and nutrition. The completion of the $21 billion Exact Sciences acquisition in March 2026 further expanded its diagnostic capabilities. In contrast, Medtronic focuses primarily on medical devices, posting first-quarter fiscal year 2027 revenue of $9.76 billion, up 13.7% year-over-year, with its Cardiovascular Portfolio growing 18.9% organically.

Medtronic Leads On Valuation Metrics

Valuation metrics currently favor Medtronic for cost-conscious investors. The company trades at a trailing price-to-earnings ratio of 23 and a forward P/E of 15, with shares priced at $90.98. This represents a discount to its 52-week high of $103.76 and a 3.69% year-to-date decline. Abbott Laboratories commands a premium, trading at a trailing P/E of 33 and a forward P/E of 17, with shares at $101.93. Despite a 17.13% year-to-date drop from its 52-week high of $134.38, Abbott’s multiple remains higher on both trailing and forward bases. Medtronic’s lower earnings multiple offers a margin of safety for investors seeking entry at a reduced valuation.

Growth Trajectories Differ Sharply

Medtronic’s growth acceleration is evident in its specialized segments, particularly Cardiac Ablation Solutions, which grew 88% in the recent quarter. Management has raised fiscal year 2027 organic revenue guidance to a range of 7.25% to 7.75%, slightly exceeding Abbott’s reaffirmed comparable sales target of 6.5% to 7.5%. Abbott’s growth is supported by broader diversification, including continuous glucose monitors that surpassed $2 billion in quarterly sales. However, Abbott faced headwinds in its Structural Heart U.S. segment, which saw sales decline by 9.8%. Medtronic’s planned separation of its Diabetes business provides a near-term catalyst that could enhance shareholder value, whereas Abbott relies on the integration of Exact Sciences to drive long-term compounding.

Risk Factors And Long-Term Outlook

Both companies face exposure to hospital spending cycles and reimbursement risks, but their risk profiles differ. Medtronic’s concentrated device focus amplifies the impact of any sector-specific downturns, though its current execution has been strong. Investors should monitor Medtronic’s earnings per share performance, as a break in its five-quarter beat streak or a miss on the fiscal year 2027 EPS guide of $5.94 to $6.00 could erode its valuation advantage. Abbott’s longer dividend streak and diversified moat provide greater durability for long-term holders, supported by a ten-year return of 202.76% compared to Medtronic’s 39.83%. The choice between the two ultimately depends on whether an investor prioritizes current income yield and lower valuation or long-term diversification and dividend aristocrat status, as noted in recent analyses by GN auto stocks/healthcare: medical device.